🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Recursion Pharmaceuticals, Inc. RXRX R2KAI

Healthcare · Biotechnology · United States
https://www.recursion.com

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

READ MORE ›
$3.59
-14.11% 1Y

Market & Price

Market Cap
$1.91B
Current Price
$3.59
High / Low (52W)
$6.79 / $2.84
Beta
1.05

Valuation

Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$1.93
Price to Book
1.86
P/S
28.69
EV/EBITDA
-2.63
Dividend Yield
-

Profitability & Returns

ROCE
-48.48%
ROE
-57.16%
ROA
-27.66%
Profit Margin
0.00%
Op Margin
-
EPS (Latest Qtr)
$-0.22
EPS (TTM)
$-1.16

Balance Sheet & Liquidity

Debt/Equity
0.07
Quick Ratio
5.15
Current Ratio
5.47
Debt
$72.38M
Total Assets
$1.47B
Current Assets
$812.85M
Working Capital
$665.14M

Ownership

Promoter Holding
2.27%
Chg in Prom Hold
-
FII / Inst Holding
68.64%
Chg in FII Hold
-0.00%

Financial Snapshot

Enterprise Value
$1.32B
Total Revenue (TTM)
$66.41M
EBITDA
$-501.23M
Free Cash Flow
$-177.80M
Operating Cash Flow
$-320.95M
Shares Outstanding
524.68M
Gross Margin
0.00%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
23.23%
Profit 5Y
-56.41%
Revenue (YoY)
-56.10%
Earnings (YoY)
-

PROS

  • Compounding revenue at 23.2% over 5 years.

CONS

  • Earnings shrank at -56.4% CAGR over 5 years.
  • Trading 47.1% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 RXRX Recursion Pharmaceuticals, Inc. R2KAI 3.59 - $1.91B - -48.48% -57.16% 23.23% -56.41%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
⚙Ad space

Quarterly Results

Figures in USD.

Metric Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 60.00K186.00K1.02M2.56M2.55M2.53M5.33M7.67M13.16M12.13M11.02M10.53M13.79M14.42M26.08M14.82M19.10M4.98M35.35M6.30M
Cost of Revenue ---------------21.83M20.16M14.69M14.28M12.49M
Gross Profit ----------------7.01M-1.06M-9.70M21.08M-6.19M
Operating Expenses ---------------184.36M175.17M162.50M129.41M122.32M
Operating Income -18.34M-18.22M-22.47M-30.48M-40.93M-46.40M-55.98M-66.19M-62.57M-69.86M-81.72M-99.55M-96.34M-100.54M-98.35M-191.37M-176.23M-172.20M-108.33M-128.50M
EBITDA ----------------182.81M-147.57M-140.37M-88.63M-102.08M
Interest Expense ---------------508.00K480.00K833.00K-11.00K350.00K
Pretax Income ----------------202.65M-171.90M-162.25M-108.10M-122.11M
Tax Provision ----------------158.00K03.00K20.00K-4.60M
Net Income -18.42M-18.94M-23.87M-30.72M-43.40M-47.43M-55.98M-65.56M-60.45M-65.33M-76.73M-93.02M-91.37M-97.54M-95.84M-202.49M-171.90M-162.25M-108.12M-117.50M
Diluted EPS -0.85-0.88-1.09-1.33-0.31-0.28-0.33-0.38-0.35-0.34-0.38-0.43-0.39-0.40-0.34-0.50-0.41-0.36-0.21-0.22
R&D Expense 12.84M13.24M16.54M24.11M29.62M33.25M32.44M38.44M40.84M46.68M55.06M70.01M67.56M73.93M74.60M129.63M128.64M121.06M-87.90M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 2.32M3.96M-39.68M43.88M58.49M74.26M
Cost of Revenue ---48.27M42.59M45.24M70.95M
Gross Profit ----8.59M1.29M13.25M3.30M
Operating Expenses ---237.13M351.35M492.25M651.43M
Operating Income -62.44M-84.61M--245.73M-350.06M-479.00M-648.13M
EBITDA ----227.66M-307.63M-426.72M-559.38M
Interest Expense ---55.00K97.00K1.57M1.81M
Pretax Income ----239.48M-332.13M-464.79M-644.89M
Tax Provision ---0-4.06M-1.13M-136.00K
Net Income -61.88M-87.01M--239.48M-328.07M-463.66M-644.76M
Diluted EPS -2.87-3.99--1.36-1.58-1.69-1.44
R&D Expense 45.81M63.32M135.27M155.70M241.23M314.42M475.27M

Compounded Sales Growth

5 Years:23.23%
1 Year:-56.10%

Compounded Profit Growth

5 Years:-56.41%
1 Year:-

Stock Price Performance

1 Year:-14.11%
6 Months:-17.85%
3 Months:-2.18%
1 Month:+8.79%

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --298.58M-701.29M653.70M1.45B1.47B
Current Assets ----569.81M438.14M714.27M812.85M
Cash & Equivalents --262.13M-549.91M391.56M594.35M743.29M
Inventory --------
Receivables ---34.00K0---
Total Liabilities --56.56M-215.48M190.26M413.82M343.26M
Current Liabilities --23.10M-100.27M93.17M187.47M147.71M
Long Term Debt ----536.00K1.10M19.02M9.56M
Total Debt ----51.01M50.67M108.49M77.97M
Total Equity -63.85M-124.27M-206.29M-485.81M463.44M1.03B1.13B
Shares Outstanding ----191.02M234.27M396.80M528.18M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -57.04M-45.40M--83.52M-287.78M-359.17M-371.81M
Investing Cash Flow -3.91M-8.74M-193.25M-10.23M260.06M-16.87M
Financing Cash Flow 120.41M246.13M-154.34M140.13M304.12M521.53M
Capital Expenditure -3.91M-5.83M--37.36M-12.55M-17.05M-8.63M
Free Cash Flow -60.95M-51.23M--120.88M-300.33M-376.22M-380.44M
Net Change in Cash ---264.07M-157.88M205.00M132.85M

Ratios (Annual)

Figures in %.

Metric Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ----21.7%2.9%22.7%4.4%
Operating Margin % -2,692.6%-2,135.7%--619.3%-797.8%-819.0%-872.8%
Net Margin % -2,668.3%-2,196.0%--603.5%-747.7%-792.7%-868.3%
ROE % 49.8%42.2%--49.3%-70.8%-44.8%-57.0%
ROCE % --30.7%--40.9%-62.5%-38.0%-48.9%

Shareholding Pattern

Insiders
2.27%
Institutions
68.64%
Public Float
70.24%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 8.23% 43.19M $155.06M
2 ARK Investment Management, LLC 7.66% 40.21M $144.36M
3 State Street Corporation 5.43% 28.49M $102.28M
4 BAILLIE GIFFORD & CO 4.51% 23.68M $84.99M
5 Vanguard Portfolio Management LLC 4.34% 22.76M $81.71M
6 Vanguard Capital Management LLC 4.24% 22.24M $79.86M
7 Softbank Group Corporation 2.60% 13.64M $48.96M
8 Geode Capital Management, LLC 2.34% 12.28M $44.07M
9 MIC Capital Management UK LLP 1.84% 9.64M $34.62M
10 Goldman Sachs Group Inc 1.16% 6.07M $21.78M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for RXRX

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space